Liraglutide,
does it really help with One-year weight loss and weight-loss maintenance in adults with obesity?
research showsLiraglutide 3.0 mg is rated B because it produces one-year weight loss and maintenance during treatment in adults with obesity. In 3,731 participants in SCALE Obesity and Prediabetes, mean weight change at 56 weeks was -8.0% with liraglutide and -2.6% with placebo, while 63.2% and 27.1%, respectively, lost at least 5%. In SCALE Maintenance, 81.4% versus 48.9% of 422 participants maintained prior diet-induced loss at 56 weeks, with greater additional loss. Core trials were sponsored by Novo Nordisk, daily injections and gastrointestinal adverse effects contribute to attrition, and regain is common after discontinuation, precluding A.
ads claimPromotion may present the average 5% to 8% loss as permanent and universal. Response varies, titration and lifestyle support matter, continued treatment is usually required, and weight can return after discontinuation.
Useful facts when choosing a product
- Saxenda is injected subcutaneously once daily, usually starting at 0.6 mg and increasing weekly to the 3.0-mg maintenance dose.
- It is added to a reduced-calorie diet and physical activity and should not be combined with another liraglutide product or another GLP-1 receptor agonist.
- Nausea, vomiting, diarrhea, and constipation are common, and dehydration, gallbladder disease, and pancreatitis require attention.
- A rodent thyroid C-cell tumor warning makes it contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2; relevance to human risk is unproven.
What the research actually shows
Pi-Sunyer 2015 randomized 3,731 adults with overweight or obesity and no diabetes to liraglutide 3.0 mg or placebo with lifestyle intervention for 56 weeks. Mean loss was 8.4 kg versus 2.8 kg, and 63.2% versus 27.1% lost at least 5%. Wadden 2013 rerandomized 422 adults who had lost at least 5% on a low-calorie diet; at 56 weeks, 81.4% versus 48.9% maintained the run-in loss, and mean change after randomization was -6.2% versus -0.2%.
Why this is classified as B (74)
A 3,731-participant 56-week trial and a separate maintenance randomized trial repeatedly confirmed direct weight change, supporting B with 74 points. Sponsor concentration, regain after stopping, daily injection and attrition, and roughly 5.4 percentage points of placebo-adjusted loss temper the score. Gastrointestinal, gallbladder, pancreatic, and thyroid warnings remain separate safety issues.
Counterpoint. Benefit is best maintained during treatment, and regain is common after stopping. If an adequate response is not achieved by about 16 weeks or adverse effects prevent continuation, discontinuation or alternatives should be discussed with the prescriber.
Rejudgment record. New verdict — Assigned B based on repeated direct weight endpoints in the 3,731-participant 56-week SCALE trial and a separate maintenance trial, tempered by Novo Nordisk sponsorship, regain after discontinuation, daily injection, and moderate effect magnitude
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| One-year weight loss in adults with obesity | B | A 3,731-participant 56-week trial found greater direct weight change than placebo. |
| One-year maintenance of prior weight loss | B | SCALE Maintenance directly confirmed maintenance rates and additional loss. |
| Permanent maintenance after discontinuation | D | Durable post-discontinuation maintenance is unproven, and regain is common. |
| Reduced major cardiovascular events in obesity without diabetes | ? | No dedicated hard-outcome randomized evidence exists for the 3.0-mg obesity population without diabetes. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Pi-Sunyer X et al. SCALE 2015 | Fifty-six-week randomized double-blind placebo-controlled multicenter trial | 3,731 | Novo Nordisk sponsored and participated in design and analysis | Mean weight change and at least 5% and 10% weight loss | At 56 weeks, change was -8.0% versus -2.6%, and 63.2% versus 27.1% lost at least 5%. | Key large direct weight evidence |
| Wadden TA et al. SCALE Maintenance 2013 | Fifty-six-week randomized double-blind placebo-controlled trial after low-calorie-diet weight loss | 422 | Sponsored by Novo Nordisk | Maintenance of run-in loss and additional weight change | Maintenance was 81.4% versus 48.9%, and post-randomization change was -6.2% versus -0.2%. | Direct replication for weight-loss maintenance |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Liraglutide x one-year weight loss and maintenance in adults with obesity — Evidence Grade B·74. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/weight/liraglutide-obesity-one-year-weight-loss-maintenance/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.